1. Home
  2. GANX
  3. GANX News

Latest Gain Therapeutics Inc. (GANX) News on January 19, 2025

All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
GANX

Zacks

3 days ago

All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
GANX

GlobeNewswire

11 days ago

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
GANX

GlobeNewswire

12 days ago

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM
GANX

TipRanks

25 days ago

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

GANX

MT Newswires

a month ago

Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
GANX

GlobeNewswire

a month ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

Gain Therapeutics To Present At Biotech Showcase 2025
GANX

GlobeNewswire

a month ago

Gain Therapeutics To Present At Biotech Showcase 2025

GANX

MT Newswires

a month ago

Roth Initiates Gain Therapeutics at Buy With $7 Price Target

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
GANX

GlobeNewswire

2 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
GANX

GlobeNewswire

3 months ago

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GANX

GlobeNewswire

3 months ago

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
GANX

GlobeNewswire

3 months ago

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
GANX

GlobeNewswire

3 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Participate at Upcoming Investor Conferences
GANX

GlobeNewswire

4 months ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
GANX

GlobeNewswire

4 months ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
GANX

GlobeNewswire

4 months ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
GANX

GlobeNewswire

4 months ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GANX

GlobeNewswire

5 months ago

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
GANX

Clinical Trials Arena

5 months ago

Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial

GANX

MT Newswires

5 months ago

Gain Therapeutics Says Phase 1 Data Confirm Safety of Parkinson's Disease Drug Candidate

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
GANX

GlobeNewswire

5 months ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

GANX

MT Newswires

5 months ago

Oppenheimer Adjusts Gain Therapeutics Price Target to $8 From $9

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
GANX

GlobeNewswire

5 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
GANX

GlobeNewswire

6 months ago

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
GANX

GlobeNewswire

6 months ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
GANX

Zacks

6 months ago

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

GANX

MT Newswires

7 months ago

HC Wainwright Trims Price Target on Gain Therapeutics to $8 From $9, Maintains Buy Rating

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
GANX

GlobeNewswire

7 months ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

GANX

MT Newswires

7 months ago

Gain Therapeutics Names Gene Mack as Interim Chief Executive Officer

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
GANX

GlobeNewswire

7 months ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
GANX

GlobeNewswire

7 months ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GANX

GlobeNewswire

7 months ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GANX

MT Newswires

7 months ago

Top Midday Decliners

GANX

MT Newswires

7 months ago

Gain Therapeutics Shares Tumble After Company Prices $11.0 Million Public Offering

GANX

MT Newswires

7 months ago

Top Premarket Decliners

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
GANX

GlobeNewswire

7 months ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

GANX

MT Newswires

7 months ago

Gain Therapeutics Plans Common Stock Offering to Finance Treatment for Neurodegenerative Disorders; Shares Fall After Hours

Gain Therapeutics Announces Proposed Public Offering
GANX

GlobeNewswire

7 months ago

Gain Therapeutics Announces Proposed Public Offering

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
GANX

GlobeNewswire

8 months ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
GANX

GlobeNewswire

8 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
GANX

Zacks

9 months ago

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GANX

GlobeNewswire

9 months ago

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
GANX

Zacks

9 months ago

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

Insiders are Piling into These 10 Healthcare Stocks in 2024
GANX

Insider Monkey

9 months ago

Insiders are Piling into These 10 Healthcare Stocks in 2024

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
GANX

Zacks

9 months ago

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
GANX

Zacks

9 months ago

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
GANX

GlobeNewswire

9 months ago

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
GANX

GuruFocus.com

10 months ago

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
GANX

GlobeNewswire

10 months ago

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
GANX

GlobeNewswire

10 months ago

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gain Therapeutics to Present at Public Ventures Discovery Day
GANX

GlobeNewswire

10 months ago

Gain Therapeutics to Present at Public Ventures Discovery Day

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
GANX

Benzinga

10 months ago

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
GANX

GlobeNewswire

10 months ago

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GANX

GlobeNewswire

a year ago

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
GANX

GlobeNewswire

a year ago

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
GANX

GlobeNewswire

a year ago

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
GANX

GlobeNewswire

a year ago

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Natural Health Trends to Report Fourth Quarter 2023 Financial Results on February 7th
GANX

GlobeNewswire

a year ago

Natural Health Trends to Report Fourth Quarter 2023 Financial Results on February 7th

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
GANX

GlobeNewswire

a year ago

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

3 Penny Stocks to Turn $999 Into $1 Million: January 2024
GANX

InvestorPlace

a year ago

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
GANX

GlobeNewswire

a year ago

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
GANX

Zacks

a year ago

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
GANX

Zacks

a year ago

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

CCSC Technology International Holdings Limited Announces Closing of Initial Public Offering
GANX

GlobeNewswire

a year ago

CCSC Technology International Holdings Limited Announces Closing of Initial Public Offering

Shareholders in Southside Bancshares (NASDAQ:SBSI) are in the red if they invested a year ago
GANX

Simply Wall St.

a year ago

Shareholders in Southside Bancshares (NASDAQ:SBSI) are in the red if they invested a year ago

Fidelity D & D Bancorp, Inc. First Quarter 2024 Dividend
GANX

GlobeNewswire

a year ago

Fidelity D & D Bancorp, Inc. First Quarter 2024 Dividend

7 A-Rated Software Stocks to Buy in January
GANX

InvestorPlace

a year ago

7 A-Rated Software Stocks to Buy in January

Vast Announces Appointment of Two Additional Directors to its Recently Expanded Board of Directors
GANX

Business Wire

a year ago

Vast Announces Appointment of Two Additional Directors to its Recently Expanded Board of Directors

Is Lakeland Industries (LAKE) a Solid Growth Stock? 3 Reasons to Think "Yes"
GANX

Zacks

a year ago

Is Lakeland Industries (LAKE) a Solid Growth Stock? 3 Reasons to Think "Yes"

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024
GANX

GlobeNewswire

a year ago

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director
GANX

GlobeNewswire

a year ago

Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director

How BankFinancial (BFIN) Stock Stands Out in a Strong Industry
GANX

Zacks

a year ago

How BankFinancial (BFIN) Stock Stands Out in a Strong Industry

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
GANX

GlobeNewswire

a year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Chimerix Appoints Lisa Decker to Board of Directors
GANX

GlobeNewswire

a year ago

Chimerix Appoints Lisa Decker to Board of Directors

Peoples Bancorp of North Carolina, Inc.'s (NASDAQ:PEBK) market cap touched US$167m last week, benefiting both individual investors who own 43% as well as institutions
GANX

Simply Wall St.

a year ago

Peoples Bancorp of North Carolina, Inc.'s (NASDAQ:PEBK) market cap touched US$167m last week, benefiting both individual investors who own 43% as well as institutions

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years
GANX

Simply Wall St.

a year ago

Investors in Natural Health Trends (NASDAQ:NHTC) have unfortunately lost 49% over the last five years

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue
GANX

Simply Wall St.

a year ago

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
GANX

Zacks

a year ago

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

Positive Signs As Multiple Insiders Buy Chimerix Stock
GANX

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Chimerix Stock

Gabelli Global Utility & Income Trust Adds June 26, 2024 as Put Date for Series B Preferred Shares
GANX

GlobeNewswire

a year ago

Gabelli Global Utility & Income Trust Adds June 26, 2024 as Put Date for Series B Preferred Shares

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences
GANX

PR Newswire

a year ago

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
GANX

GlobeNewswire

a year ago

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
GANX

GlobeNewswire

a year ago

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
GANX

GlobeNewswire

a year ago

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Smart Share Global Limited (NASDAQ:EM) Q3 2023 Earnings Call Transcript
GANX

Insider Monkey

a year ago

Smart Share Global Limited (NASDAQ:EM) Q3 2023 Earnings Call Transcript

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
GANX

GlobeNewswire

a year ago

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Gabelli Global Utility & Income Trust Alerts Series B Preferred Shareholders of Upcoming Put Date on December 26, 2023
GANX

GlobeNewswire

a year ago

Gabelli Global Utility & Income Trust Alerts Series B Preferred Shareholders of Upcoming Put Date on December 26, 2023

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
GANX

GlobeNewswire

a year ago

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

Purple Introduces Two New Pillows That Offer Deeper Sleep Through Customization and Portability
GANX

PR Newswire

a year ago

Purple Introduces Two New Pillows That Offer Deeper Sleep Through Customization and Portability

Purple Innovation, Inc. (NASDAQ:PRPL) Q3 2023 Earnings Call Transcript
GANX

Insider Monkey

a year ago

Purple Innovation, Inc. (NASDAQ:PRPL) Q3 2023 Earnings Call Transcript

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
GANX

Zacks

a year ago

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

Clarus Corporation (NASDAQ:CLAR) Q3 2023 Earnings Call Transcript
GANX

Insider Monkey

a year ago

Clarus Corporation (NASDAQ:CLAR) Q3 2023 Earnings Call Transcript

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses
GANX

Simply Wall St.

a year ago

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

P3 Health Partners Schedules Third-Quarter 2023 Earnings Release and Conference Call
GANX

Business Wire

a year ago

P3 Health Partners Schedules Third-Quarter 2023 Earnings Release and Conference Call

GANX

Thomson Reuters StreetEvents

a year ago

Q3 2023 Abcellera Biologics Inc Earnings Call

GANX

GuruFocus.com

a year ago

Shore Bancshares Inc (SHBI) Reports Q3 2023 Net Loss of $6.4 Million Due to Merger Activity

Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress
GANX

GuruFocus.com

a year ago

Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress

Natural Health Trends Corp. (NASDAQ:NHTC) Q3 2023 Earnings Call Transcript
GANX

Insider Monkey

a year ago

Natural Health Trends Corp. (NASDAQ:NHTC) Q3 2023 Earnings Call Transcript

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
GANX

GlobeNewswire

a year ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

GANX

Associated Press Finance

a year ago

Shore Bancshares: Q3 Earnings Snapshot

Share on Social Networks: